The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy.
The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy.
复制标题
左侧RAS野生型转移性结直肠癌患者的最佳一线治疗：双药方案或三药方案治疗
DOI：
10.3389/fphar.2022.1015510
复制
发表时间：
2022
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
There are many treatments for metastatic colorectal cancer (mCRC). Among them, uncertainty remains especially concerning the clinical benefit of different regimens for left-sided RAS wild-type (WT) mCRC in the triple-drug therapy era. No studies have been conducted to answer this critical clinical issue. We performed a comprehensive analysis of published data and real-world data. First, we conducted analyses of the published trials to show the landscape of efficacy and safety in the treatments of left-sided RAS WT mCRC. Then, we initiated a multicenter real-world study as the validation dataset. This study included six published randomized controlled trials (RCTs) and a total of 1925 patients. The double-drug regimen plus cetuximab/panitumumab (D + C/P) achieved the longest overall survival (OS) in patients with left-sided mCRC (HR = 0.74, 95%CI: 0.57–0.98), while triple-drug regimen with bevacizumab (T + B, HR = 1.1, 95%CI: 0.63–2.0), compared with double-drug with bevacizumab (D + B). The D + C/P had the highest overall response rate (ORR) in patients with left-sided mCRC (OR = 1.8, 95%CI: 0.89–3.8), while T + B (OR = 1.8, 95%CI: 0.70–4.8), compared with D + B. The multicenter real-world cohort showed the double-drug regimen plus cetuximab had longer progression-free survival (PFS) in left-sided mCRC patients than the triple-drug regimen with bevacizumab. The safety analysis showed the incidence of the adverse events (grade≥3) in the triple-drug therapy plus bevacizumab was higher than that in the double-drug therapy plus cetuximab/panitumumab. This work demonstrates the ranking of three regimens for therapeutic efficacy and safety in patients with left-sided RAS WT mCRC. The double-drug regimen plus cetuximab/panitumumab appears more effective and safer than double-drug and triple-drug based regimens with bevacizumab. Further trials and cohort analyses on this topic would increase confidence in these results.
登录
查看更多内容
DOI：
10.4103/0253-7184.69003
发表时间：
2010-01
影响因子：
0.4
作者：
Aslam S;Emmanuel P
通讯作者：
Emmanuel P
影响因子：
50.5
作者：
Fornaro, L.;Lonardi, S.;Falcone, A.
通讯作者：
Falcone, A.
影响因子：
5.8
作者：
Hurwitz, Herbert, I;Tan, Benjamin R.;Bendell, Johanna
通讯作者：
Bendell, Johanna
影响因子：
28.4
作者：
Petrelli, Fausto;Tomasello, Gianluca;Barni, Sandro
通讯作者：
Barni, Sandro
DOI：
10.1001/jama.2017.7105
发表时间：
2017-06-20
期刊：
JAMA
影响因子：
--
作者：
Venook AP;Niedzwiecki D;Lenz HJ;Innocenti F;Fruth B;Meyerhardt JA;Schrag D;Greene C;O'Neil BH;Atkins JN;Berry S;Polite BN;O'Reilly EM;Goldberg RM;Hochster HS;Schilsky RL;Bertagnolli MM;El-Khoueiry AB;Watson P;Benson AB 3rd;Mulkerin DL;Mayer RJ;Blanke C
通讯作者：
Blanke C